Non-Alcoholic Steatohepatitis Treatment Market Size to Exceed $13.83 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Non-Alcoholic Steatohepatitis Treatment Market Grown from 2024 to 2025?
In the last few years, the market for non-alcoholic steatohepatitis treatment has witnessed a significant upsurge. Its expansion is set to continue, rising from $2.6 billion in 2024 to $3.6 billion in 2025 with a compound annual growth rate of 38.5%. Various factors have contributed to the growth observed in the historic period such as the increasing occurrence of NASH, enhanced awareness and diagnosis, lifestyle modifications and growing obesity crises, in-depth clinical research, improvements in healthcare infrastructure and accessibility, regulatory backing, and clinical trials.
What Growth Rate Is Anticipated for the Non-Alcoholic Steatohepatitis Treatment Market in the Coming Years?
The market for non-alcoholic steatohepatitis treatment is anticipated to witness a significant surge in the coming years, with its value projected to reach $13.83 billion by 2029, expanding at a compound annual growth rate (CAGR) of 40.0%. The expected growth during the forecast period can be credited to progress in drug discovery, heightened disease understanding, increasing incidence and risk factors, along with a shift towards personalized healthcare. Key trends predicted for the coming period include a more patient-focused approach, technological innovation, targeted treatments, evolving regulatory environment, and advances in research.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
Who Are the Leading Companies in the Non-Alcoholic Steatohepatitis Treatment Market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
What Are the Key Drivers of the Non-Alcoholic Steatohepatitis Treatment Market?
Insulin resistance’s growing prevalence has been a major contributor to the expansion of the non-alcoholic steatohepatitis treatment market. When insulin resistance happens, muscle, fat, and liver cells don’t respond properly to insulin, making glucose absorption from the blood difficult, which in turn leads to high blood sugar. This condition is often associated with an unhealthy lifestyle, overconsumption of sugar, and genetic factors. Insulin resistance has become more common due to the increase in diabetes and other liver-related conditions, which are managed by non-alcoholic steatohepatitis treatment. For example, as per the latest report from the International Diabetes Federation, a global diabetes community based in Belgium, in January 2022, 537 million individuals (20-79 years old) are currently affected by diabetes, representing one in ten individuals. This figure is predicted to rise to 643 million by 2030, and 783 million by 2045. Additionally, the American Cancer Society, a nonprofit cancer advocacy group in the US, anticipates new liver cancer cases in 2024 to be 41,630, up from 41,210 in 2023. Consequently, the growing prevalence of insulin resistance due to various liver and diabetes diseases is predicted to boost the non-alcoholic steatohepatitis treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp
What Are the Key Market Segments in the Non-Alcoholic Steatohepatitis Treatment Industry?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
What Are the Latest Trends in the Non-Alcoholic Steatohepatitis Treatment Market?
The evolution of non-alcoholic steatohepatitis (NASH) medication is emerging as a significant trend in the non-alcoholic steatohepatitis therapy market. Numerous firms are directing their resources towards the invention of innovative drugs aimed at liver disease treatment, minimizing the side effects. For instance, Pfizer Inc., a leading American pharmaceutical and biotechnology corporation, was granted fast-track designation in May 2022 by the U.S. Food and Drug Administration (FDA) to expedite the development process of its NASH drug, specifically ervogastat and clesacostat. Fast Track is a designed program to expedite the development of Pfizer’s investigative combination therapy for non-alcoholic steatohepatitis (NASH) with liver fibrosis, namely ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
Access The Full Report Here:
What Are the Key Regional Markets in the Non-Alcoholic Steatohepatitis Treatment Industry?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595
This Report Delivers Insight On:
1. How big is the non-alcoholic steatohepatitis treatment market, and how is it changing globally?
2. Who are the major companies in the non-alcoholic steatohepatitis treatment market, and how are they performing?
3. What are the key opportunities and risks in the non-alcoholic steatohepatitis treatment market right now?
4. Which products or customer segments are growing the most in the non-alcoholic steatohepatitis treatment market?
5. What factors are helping or slowing down the growth of the non-alcoholic steatohepatitis treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
